NightHawk Biosciences, Inc.
(NYSE Amex Equities : NHWK)

( )
NHWK PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.58%177.120.7%$1156.59m
LLYEli Lilly & Co. 0.96%372.061.1%$1068.92m
MRKMerck & Co., Inc. 1.06%110.080.7%$1002.54m
PFEPfizer Inc. 1.09%50.250.9%$935.84m
ABBVAbbVie, Inc. 0.98%165.321.9%$895.13m
BMYBristol-Myers Squibb Co. 0.01%79.931.1%$742.00m
AZNAstraZeneca Plc 0.42%68.851.0%$354.37m
HZNPHorizon Therapeutics Plc -0.57%96.305.4%$286.44m
GSKGSK Plc -2.74%36.880.3%$251.05m
IDXXIDEXX Laboratories, Inc. 1.13%420.103.9%$191.38m
NVSNovartis AG 1.09%91.730.2%$188.48m
CTLTCatalent, Inc. -2.05%47.231.9%$170.45m
ALNYAlnylam Pharmaceuticals, Inc. 5.32%231.338.0%$168.15m
NVONovo Nordisk A/S -0.42%125.260.1%$152.07m
SNYSanofi -1.26%47.940.2%$138.09m

Company Profile

NightHawk Biosciences, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.